Healthcare practitioners’ diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey

Hartleb, Marek; Mastalerz-Migas, Agnieszka; Kowalski, Piotr; Popović, B.; Proga, Katarzyna; Cywińska-Durczak, Beata

doi:10.1097/meg.0000000000002288

Cited by 10 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lastly, the data were not gathered with validated questionnaires. However, the questions were easy to understand, and similar basic questionnaires are often used without the need for validation [ 24 , 25 ]. We provided data on the use of drotaverine within a real-world setting in a large and representative sample of patients and GPs, which is the strength of our study.…”

Section: Discussionmentioning

confidence: 99%

Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data

Eder

Kowalski

Mastalerz-Migas

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

In Poland, drotaverine is the most frequently purchased antispasmodic, yet there is a paucity of real-world data on its use. We evaluated the profiles of patients who used drotaverine, and we investigated prescription patterns among general practitioners (GPs). In this cross-sectional, questionnaire-based study, we asked patients who purchased drotaverine about their reasons for using it, its perceived efficacy, satisfaction with treatment, and physician consultation. We also asked GPs about the status of drotaverine in their practice. Among 650 recruited patients, 74% used drotaverine for pain, 67% for cramps, and 19% for abdominal discomfort. Approximately 83% of patients purchased drotaverine without a physician’s advice. Patients who used it after a physician’s advice were more frequently female, older, and less educated. For all symptoms, mean severity scores decreased by ~5 points (0–10 scale) after the first dose. Ninety-eight percent of patients were satisfied with drotaverine. Among 210 GPs, the percentages prescribing drotaverine were: 42% for irritable bowel syndrome, 89% for cholelithiasis, 60% as supportive therapy for urinary infections, 89% for nephrolithiasis, and 75% for menstruation pain. The GPs perceived drotaverine as more useful, effective, and tolerable than other drugs for abdominal pain or cramps. Drotaverine significantly reduced the severity of all symptoms for which it was taken, and it was perceived as effective and tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data

Eder

Kowalski

Mastalerz-Migas

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…RESTORE було обсерваційним, неінтервенційним, ретроспективним, наскрізним дослідженням, у якому були зібрані дані реальної практики, надані відібраними досвідченими гастроентерологами (ГЕ) (n = 95) та лікарями загальної практики (ЛЗП) (n = 115) у Польщі [1]. Основною метою спостереження пацієнтів, які відвідують ГЕ (n = 380), була реєстрація найбільш значущих симптомів, пов'язаних із НАЖХП.…”

Section: гастроентерологи й лікарі загальної практики рекомендують за...unclassified

Дані Реальної Практики Свідчать На Користь Застосування Есенціальних Фосфоліпідів При Неалкогольній Жировій Хворобі Печінки

Cywinska-Durczak¹,

Popović²

2022

Evid Self Med

Self Cite

View full text Add to dashboard Cite

Поширеність неалкогольної жирової хвороби печінки (НАЖХП) збільшується по всьому світі, так само як і довгострокові ризики для здоров’я тих, кого вона вражає. Поряд зі змінами в способі життя та дієтою, фармакотерапія є третім чинником, на яке спирається лікування НАЖХП. Дані реальної практики підтверджують високу цінність есенціальних фосфоліпідів у лікуванні НАЖХП та важливість дотримання режиму лікування під час довготривалої терапії.

show abstract

“…RESTORE was an observational, non-interventional, retrospective, cross-sectional survey that collected real-world data from selected, experienced gastroenterologists (GEs) (n = 95) and general practitioners (GPs) (n = 115) in Poland [1]. The major aim of the survey of patients visiting GEs (n = 380) was, to record the most relevant symptoms related to NAFLD.…”

Section: Gastroenterologists and General Practitioners Recommend Esse...mentioning

confidence: 99%

“…in Poland [1] Since NAFLD is a chronic disease, 59% of GEs and 62% of GPs recommended long-term treatment. Fig.…”

Section: Information Regarding Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Real-world data support the use of essential phospholipids in non-alcoholic fatty liver disease

Cywinska-Durczak¹,

Popović²

2022

Evid Self Med

Self Cite

View full text Add to dashboard Cite

show abstract

Healthcare practitioners’ diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey

Abstract: Supplemental Digital Content is available in the text.

Cited by 10 publications

References 44 publications

Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data

Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners—An Observational, Retrospective, Cross-Sectional Study Using Real-World Data

Дані Реальної Практики Свідчать На Користь Застосування Есенціальних Фосфоліпідів При Неалкогольній Жировій Хворобі Печінки

Real-world data support the use of essential phospholipids in non-alcoholic fatty liver disease

Contact Info

Product

Resources

About